Unicycive Therapeutics, Inc. 10-Q

ITEM 5. OTHER INFORMATION On August 13, 2025, we filed a Certificate of Correction with the Secretary of State of Delaware (“Certificate of Correction”) for our Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock (“Series A Certificate of Designation”) filed with the Secretary of State of Delaware on March 13, 2024. The Certificate of Correction was filed to correct certain scrivener’s errors in the Series A Certificate of Designation with respect to adjustments for stock dividends and stock splits under Section 7(a) of the Series A Certificate of Designation which inadvertently stated that the Conversion Price for each series of Series A Preferred Stock adjusted upon any stock dividends and stock splits if such actions occurred at any time when any shares of Series A Preferred Stock were outstanding whereas there should only be an adjustment to the Conversion Price of a particular series of Series A Preferred Stock for any shares of such series of Series A Preferred Stock outstanding at the time of the stock dividend or stock split. Pursuant to Section 103(f) of the Delaware General Corporation Law, the correction was effective as of March 14, 2024, except as to those persons who are substantially and adversely affected by the correction, and as to those persons the correction was effective as of August 13, 2025. The foregoing description of the Certificate of Correction is qualified in its entirety by reference to the full text of the Certificate of Correction, which is filed herewith as Exhibit 3.1 and incorporated herein by reference. ITEM 6. EXHIBITS Exhibit No. Description 3.1 Certificate of Correction to Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Voting Preferred Stock filed with the Delaware Secretary of State on August 13, 2025 31.1 Certification of Principal Executive Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act. 31.2 Certification of Principal Financial Officer required under Rule 13a-14(a)/15d-14(a) under the Exchange Act. 32.1 Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 32.2 Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit were omitted by means of marking such portions with an asterisk because such information is both not material and is the type that the Company treats as private or confidential. 40 SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 14th day of August, 2025. Signature Title Date /s/ Shalabh Gupta Chief Executive Officer, President and Chairman August 14, 2025 Shalabh Gupta (Principal Executive Officer) /s/ John Townsend Chief Financial Officer August 14, 2025 John Townsend (Principal Financial and Accounting Officer) 41